Predict your next investment

INTERNET | Stealth Mode

See what CB Insights has to offer

Stage

Debt | Alive

Total Raised

$130K

Last Raised

$130K | 4 yrs ago

About QCDx

QCDx is currently operating in stealth mode.

QCDx Headquarter Location

400 Farmington Avenue

Farmington, Connecticut, 0603,

United States

Latest QCDx News

QCDx Announces Sale of the RareScope to the Carole and Ray Neag Comprehensive Cancer Center at UConn Health for Use in Clinical Research

Jan 21, 2020

QCDx , a private biotech company that has developed a breakthrough Circulating Tumor Cell (CTC) liquid biopsy from a simple blood draw, today announced the sale of the proprietary RareScope™ instrument to the Carole and Ray Neag Comprehensive Cancer Center at UConn Health. The Rare Scope will be used in clinical cancer research. “The RareScope can detect and isolate intact and live Circulating Tumor Cells from a blood sample of a cancer patient after analyzing every single nucleated cell,” said Dr. Pramod K. Srivastava PhD MD, Director of the Carole and Ray Neag Comprehensive Cancer Center at UConn Health and a world authority in cancer immunology. “We intend to use the ability of the RareScope to obtain a deep look into the genomes of cancer cells in patients undergoing standard-of-care and experimental treatments.” “We are proud that the Carole and Ray Neag Comprehensive Cancer Center at UConn Health has selected the RareScope as the optimal method to detect and immunologically characterize CTCs from patients in clinical studies of personalized therapeutics with potential to cure metastatic cancer,” said Dr. Triantafyllos (Fyl) Tafas, Founder and CEO of QCDx. “Our technology tackles the ultimate challenge presented by cancer continually changing in the patient’s body and often becoming resistant to a chosen therapy. With sensitive CTC detection and characterization, we aim to reveal early indications of disease progression and new molecular targets that can be used for real-time, personalized treatment.” About CTC Liquid Biopsy: Cells from solid tumors enter the blood stream very early in the tumor development, become CTCs and eventually cause metastasis. Tumors are heterogeneous and CTCs reflect their different genetic profiles. Today, the standard practice for solid cancers detection are biopsies, which are invasive, cannot be used repeatedly and are ineffective in metastatic disease and assessing treatment effectiveness. CTC liquid biopsies from a simple blood draw can be repeated frequently to reveal the disease heterogeneity. The ultimate CTC diagnostic engine must accurately detect and characterize different CTC phenotypes from the original tumor and potential, metastatic sites. Additionally, isolate intact and live CTCs for downstream genomic, transcriptomic, epigenetic and other molecular analyses that can provide guidance for personalized and timely cancer treatment. About UConn Health: UConn Health is Connecticut’s only public academic medical center. Based on a 206-acre campus in Farmington, UConn Health has a three-part mission: research, teaching and patient care. Home to the UConn School of Medicine, School of Dental Medicine and UConn John Dempsey Hospital with nearly 5,000 employees supporting nearly 1,000 students, over 800,000 annual patient visits, and innovative scientific research contributing to the advancement of medicine. For more information, visit health.uconn.edu. About QCDx: QCDx develops, manufactures and markets tools and integrated systems to detect and monitor cancer at the single cell level. Our technology provides innovative solutions for analyzing all nucleated cells within a blood sample, in an immobilized, multi-million cell suspension, detects intact and live CTCs and isolates for downstream, single-cell molecular analyses. Our technology and products aim to accelerate cancer research and treatment and ultimately transforming healthcare. For more information, visit http://www.qcd-x.com . Stay in touch on LinkedIn . For the original version on PRWeb visit: https://www.prweb.com/releases/qcdx_announces_sale_of_the_rarescope_to_the_carole_and_ray_neag_comprehensive_cancer_center_at_uconn_health_for_use_in_clinical_research/prweb16845956.htm

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing QCDx

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

QCDx is included in 1 Expert Collection, including Cancer Liquid Biopsies.

C

Cancer Liquid Biopsies

105 items

Products/services that analyze tumor-derived biomarkers (ctDNA, CTCs, exosomes) in blood/urine/other non-invasive liquid specimens to detect cancer earlier, guide treatment, and monitor progress. *Data fields manually updated as new information becomes available.'

QCDx Patents

QCDx has filed 2 patents.

The 3 most popular patent topics include:

  • Oncology
  • Rare diseases
  • Biopsy
patents chart

Application Date

Grant Date

Title

Related Topics

Status

6/27/2018

Rare diseases, Oncology, Microscopy, Transcription factors, Biotechnology

Application

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

Application Date

6/27/2018

00/00/0000

Grant Date

00/00/0000

Title

Subscribe to see more

Related Topics

Rare diseases, Oncology, Microscopy, Transcription factors, Biotechnology

Subscribe to see more

Status

Application

Subscribe to see more

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.